Women’s Dissatisfaction With Body Image Can Affect Smoking

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

Women smokers who overestimate their body size may be more likely to continue smoking, said researchers at The Miriam Hospital in Providence. Results of a study led by Teresa K. King, PhD, of the hospital’s Center for Behavioral and

Women smokers who overestimate their body size may be more likely to continue smoking, said researchers at The Miriam Hospital in Providence. Results of a study led by Teresa K. King, PhD, of the hospital’s Center for Behavioral and Preventive Medicine, were presented at a recent meeting of the Society of Behavioral Medicine.

Participants in the study were 141 women smokers who had been recruited as part of a smoking cessation trial at the hospital. The women completed an evaluation to ascertain their perceptions of their body size and whether they were satisfied with those perceptions.

At the end of the treatment, only 4 (18.2%) of the 22 women who overestimated their body size relative to their peers had managed to stay off cigarettes, compared with 12 (50%) of the 24 women who underestimated their body size, and 28 (29.5%) of the 95 women who neither overestimated nor underestimated their body size.

The results suggest that body image may play an important role in the smoking behavior of women. Women who overestimate their body size and/or evaluate their body negatively may be more likely to continue smoking--perhaps to prevent weight gain.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content